inclusion criteria: male and female subjects aged ≥18 years of age confirmed coronavirus infection positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 any other diagnostic test accepted by local regulatory authorities must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

inclusion criteria: male and female subjects aged ≥18 years of age confirmed coronavirus infection positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 any other diagnostic test accepted by local regulatory authorities must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

inclusion criteria: 1. male and female subjects aged ≥18 years of age 2. confirmed coronavirus infection 1. positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid 2. viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 3. any other diagnostic test accepted by local regulatory authorities 3. must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) 4. female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) 5. non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) 6. subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

inclusion criteria: 1. male and female subjects aged ≥18 years of age 2. confirmed coronavirus infection 1. positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid 2. viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 3. any other diagnostic test accepted by local regulatory authorities 3. must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) 4. female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) 5. non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) 6. subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

inclusion criteria: 1. male and female subjects aged ≥18 years of age 2. confirmed coronavirus infection 1. positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid 2. viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 3. any other diagnostic test accepted by local regulatory authorities 3. must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) 4. female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) 5. non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) 6. subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures

inclusion criteria: 1. male and female subjects aged ≥18 years of age 2. confirmed coronavirus infection 1. positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for covid-19 nucleic acid 2. viral gene sequences in respiratory or blood specimens that are highly homologous to covid-19 3. any other diagnostic test accepted by local regulatory authorities 3. must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (score of 4 or 5 on who ordinal clinical scale) 4. female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s) 5. non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s) 6. subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures